Instagram Outage Disrupts Thousands of U.S. Users 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
CAMBRIDGE, Mass., Oct. 31, 2016 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.
25th Annual Credit Suisse Healthcare Conference
Monday, November 7, 2016 at 1:00 p.m. MST in Scottsdale, AZ
Stifel 2016 Healthcare Conference
Wednesday, November 16, 2016 at 11:45 a.m. EST in New York, NY
The audio webcast of each presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of each presentation will be posted on the Momenta website approximately one hour after the event.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected]
